AstraZeneca

AstraZeneca EBIT Growth

Year-over-Year EBIT Growth of AstraZeneca (AZN) as of Oct 19, 2026.

EBIT Growth

-

Last updated:

Year-over-Year EBIT Growth of AstraZeneca is 2026 - . Year-over-Year EBIT Growth of AstraZeneca was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC, listed on the stock market with ticker AZN, operates as a biopharmaceutical company focused on prescription medicines. Founded in the UK, it is headquartered in Cambridge, United Kingdom. The company develops, manufactures, and commercializes pharmaceutical products including Imjudo, Tagrisso, Imfinzi, Lynparza, Enhertu, and others. AstraZeneca's products target various therapeutic areas such as oncology, cardiovascular, respiratory, and immunology. The company went public on May 17, 1993. Its website is https://www.astrazeneca.com. AstraZeneca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AstraZeneca stock

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's AstraZeneca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — AstraZeneca

All Key Metrics — AstraZeneca